Supreme Court: Foreign Judgment Unenforceable in India Without Fair Opportunity to Defend  ||  Supreme Court: High Court Cannot Decide Appeal Pending Before Statutory Authority Due to Delay  ||  Supreme Court: SDO Lacks Authority to Change Land Classification under UP Zamindari Abolition Act  ||  Supreme Court: Man Not Liable For Maintenance if DNA Test Proves He is Not the Child’s Father  ||  SC: Prison Must Not Dilute Rights of Disabled Inmates; Oversight Given to High-Powered Panel  ||  Delhi High Court: Judges Would Have to Recuse if Children as Central Govt Counsel is Treated as Bias  ||  Delhi HC: Fresh Tenders Allowed Despite Existing Contracts; Anticipatory Grievances Not Entertained  ||  Delhi High Court: Judges Cannot Respond Publicly; Criticism Must Be Responsible and Evidence-Based  ||  J&K&L High Court: IO Not Bound By FIR; Can Modify Offences in Final Chargesheet U/S 173 CrPC  ||  Supreme Court: Brief Service Breaks Do Not Bar Ad Hoc Employees From Regularisation    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved